Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024
SUZHOU,China,Nov. 11,2024-- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033,a high-concentration subcutaneous co-formulation consisti